Loading...
•
Jun 30, 2023
Spyre Q2 2023 Earnings Report
Aeglea BioTherapeutics's financial position was updated and shifted its focus to IBD after acquiring Spyre's assets.
Key Takeaways
Aeglea BioTherapeutics reported second quarter 2023 financial results, including $236.7 million in cash and cash equivalents, $0.7 million in revenue, and a net loss of $217.1 million. The company completed the acquisition of Spyre Therapeutics, raised $210.0 million in gross proceeds, and sold global rights to pegzilarginase for $15.0 million upfront and up to $100.0 million in contingent milestone payments.
Completed the asset acquisition of Spyre Therapeutics, shifting focus to inflammatory bowel disease (IBD).
Raised $210.0 million in gross proceeds through a private placement.
Sold global rights to pegzilarginase for $15.0 million upfront and up to $100.0 million in contingent milestone payments.
Cash and cash equivalents and restricted cash totaled $236.7 million as of June 30, 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...